ФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙ: ТЕРАПЕВТИЧЕСКИЕ ВОЗМОЖНОСТИ КОНТРОЛЯ ЧАСТОТЫ СЕРДЕЧНЫХ СОКРАЩЕНИЙ
Аннотация
Резюме. Пациенты с наличием постоянной формы фибрилляции предсердий (ФП) имеют высокий риск сердечно-сосудистых осложнений. Постоянная форма ФП ассоциируется с увеличением смертности, частоты инсульта и других тромбоэмболических осложнений, госпитализаций, развитием сердечной недостаточности, снижением переносимости физической нагрузки и дисфункцией левого желудочка, ухудшением качества жизни. В статье представлены возможности контроля частоты сердечных сокращений у пациентов с постоянной формой ФП.
Литература
Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160(11):760-773. https://doi.org/10.7326/M13-1467.
Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122-133. https://doi.org/10.1111/j.1540-8159.2012.03513.x.
Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients taking digoxin – analysis from the AFFIRM study. Eur Heart J. 2013;34(20):1481-1488. https://doi.org/10.1093/eurheartj/ehs348.
Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K, Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34(20):1489-1497.https://doi.org/10.1093/eurheartj/eht120.
Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33(2):304-410. https://doi.org/10.1016/s0735-1097(98)00561-0.
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha DS. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. https://doi.org/10.1136/bmj.h4451.
Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65(25):2691-2698. https://doi.org/10.1016/j.jacc.2015.04.045.
Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, Hillege HL, Tuininga YS, Van Veldhuisen DJ, Ranchor AV, Van Gelder IC. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58(17):1795-1803. https://doi.org/10.1016/j.jacc.2011.06.055.
Zehender M, Hohnloser S, Müller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol. 1992;19(5):1054-1059. https://doi.org/10.1016/0735-1097(92)90294-w.
Tse HF, Lam YM, Lau CP, Cheung BM, Kumana CR. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. Clin Exp Pharmacol Physiol. 2001;28(5-6):446-450. https://doi.org/10.1046/j.1440-1681.2001.03454.x.
Shljahto EV, editor. Kardiologija: nacionalnoe rukovodstvo. 2nd ed. Moscow: GEOTAR-Media; 2021. Chap. 19, Revishvili ASh, Sulimov VA. Fibrilljacija i trepetanie predserdij; p. 472-489. (Russian).
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan G-A, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau J-P, Lettino M, Lip GYH, Pinto FJ, Neil Thomas G, Valgimigli M, Van Gelder IC, Bart Van Putte P, Watkins CL. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):234-329. https://doi.org/10.15829/1560-4071-2021-4701. https://www.elibrary.ru/nnletb. (Russian).
Arakelyan MG, Bockeria LA, Vasilieva EYu, Golitsyn SP, Golukhova EZ, Gorev MV, Davtyan KV, Drapkina OM, Kropacheva ES, Kuchinskaya EA, Lajovich LYu, Mironov NYu, Mishina IE, Panchenko EP, Revishvili ASh, Rzayev FG, Tatarsky BA, Utsumueva MD, Shakhmatova OO, Shlevkov NB, Shpektor AV, Andreev DA, Artyukhina EA, Barbarash OL, Galyavich AS, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):190-260. https://doi.org/10.15829/1560-4071-2021-4594. https://www.elibrary.ru/fuzaad. (Russian).
Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Løchen ML, Lumbers RT, Maesen B, Mølgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176.
